Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Youji Fukumoto is active.

Publication


Featured researches published by Youji Fukumoto.


Gastric Cancer | 2009

Serum interleukin-6 and -10 levels in patients with gastric cancer

Masahide Ikeguchi; Tomoko Hatada; Manabu Yamamoto; Takanori Miyake; Tomonori Matsunaga; Youji Fukumoto; Yoshinori Yamada; Kenji Fukuda; Hiroaki Saito; Shigeru Tatebe

BackgroundInterleukin-6 (IL-6) is known to be a multifunctional cytokine and IL-10 is an immunosuppressive factor. Both have been reported to be related to the disease prognosis in some human solid tumors. In the present study, we evaluated the clinical significance of preoperative serum IL-6 and IL-10 levels as new tumor markers in patients with gastric cancer (GC).MethodsPreoperative serum samples from 90 patients with GC and 9 normal healthy volunteers were assayed. Levels of IL-6 and IL-10 were determined by enzyme-linked immunosorbent assay (ELISA). The clinical significance of serum IL-6 and IL-10 levels was evaluated and compared with serum carcinoembryonic antigen (CEA) levels and serum C-reactive protein (CRP) levels in these patients.ResultsThe serum level of IL-6 was significantly higher in the GC patients than in the healthy subjects. Serum IL-6 levels were strongly correlated with CRP levels, but did not correlate with CEA or carbohydrate antigen (CA) 19-9 levels. Serum IL-10 levels did not correlate with CEA, CA19-9, or CRP. Strong positive correlations between serum IL-6 levels and tumor size and tumor stage were observed. On the other hand, IL-10 did not correlate with such clinicopathological findings of tumors. However, high serum IL-10 levels were associated with a worse prognosis in the GC patients, independently of their tumor stage.ConclusionThese findings indicate that serum IL-6 may suggest gastric cancer progression. On the other hand, IL-10 may play an important role in host immunity and the prognosis of GC patients.


World Journal of Surgery | 2006

Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach

Hiroaki Saito; Youji Fukumoto; Tomohiro Osaki; Kenji Fukuda; Shigeru Tatebe; Shunichi Tsujitani; Masahide Ikeguchi

BackgroundCarcinoma arising in the cardioesophageal junction is a distinct clinical entity compared with tumors located in other regions of the stomach. The prognosis for adenocarcinoma of the upper stomach is considered to be relatively poorer than carcinomas of the more distal stomach. We have therefore investigated patients with carcinoma of the gastric cardia in order to evaluate the underlying cause of this poor prognosis.Materials and MethodsClinicopathologic features and postoperative prognosis of 101 patients with carcinoma of the cardia were evaluated and compared with findings on 1884 patients with tumors in other regions of the stomach.ResultsTumors of the cardia had a mean size of 6.8 cm, which was significantly larger than the mean size of 5.9 cm for tumors found in the middle- and lower third of the stomach. The incidence of serosal invasion, lymph node metastasis, and lymphatic and blood vessel invasion was higher in association with adenocarcinoma of the cardia than with adenocarcinoma in remaining parts of the stomach. In the analysis of patients who had undergone curative resection, the 5-year survival rates were 61.6, 79.1, and 82.6% in patients with carcinoma of the cardia, upper one-third, and remaining middle- and lower one-third of the stomach, respectively, and the differences were statistically significant. Multivariate analysis indicated that adenocarcinoma of the gastric cardia is an independent prognostic factor. With regard to the site of recurrence, both lymph node and hematogenous recurrence were observed more frequently in the cardia than in the remaining parts of the stomach.ConclusionsOur data indicate that the prognosis of patients with adenocarcinoma of the gastric cardia is extremely poor. To improve their prognosis, new treatments in addition to gastrectomy with extensive lymph node dissection are needed.


Surgery Today | 2009

Recent results of therapy for scirrhous gastric cancer

Masahide Ikeguchi; Takanori Miyake; Tomoyuki Matsunaga; Manabu Yamamoto; Youji Fukumoto; Yosinori Yamada; Kenji Fukuda; Hiroaki Saito; Shigeru Tatebe; Shunichi Tsujitani

The prognosis of patients with scirrhous gastric cancer (SGC) is extremely poor. However, recent advances in therapeutic strategies against SGC, using effective anticancer drugs, have prolonged the survival of patients with SGC. This paper reviews the recent therapeutic outcomes of this type of gastric cancer and introduces a new treatment protocol for SGC.


Surgery Today | 2009

Free jejunal graft reconstruction after resection of neck cancers: Our surgical technique

Masahide Ikeguchi; Takanori Miyake; Tomoyuki Matsunaga; Manabu Yamamoto; Youji Fukumoto; Yosinori Yamada; Kenji Fukuda; Hiroaki Saito; Shigeru Tatebe; Shunichi Tsujitani

Locally advanced carcinomas arising in the hypopharynx, cervical esophagus, or thyroid are traditionally treated by resection of the hypopharynx and cervical esophagus. Various methods of reconstruction aiming to achieve safety and functionality have been reported, including the myocutaneous flap and the free jejunal graft. With advances in microscopic surgery, the free jejunal transplant is now used dominantly; however, this procedure is not without major risks. In this review we examine the short- and long-term complications of this procedure. We also describe our technique of free jejunal graft reconstruction after pharyngoesophagectomy and total laryngectomy with definitive tracheostomy. We used free jejunal graft reconstruction after resection with hypopharyngeal cancer or thyroid cancers in 22 patients. Twenty-one of these patients acquired a good quality of life, but one died after loss of the jejunal graft. Thus, using a free jejunal graft for reconstruction of the hypopharynx or cervical esophagus can be very useful in improving the quality of life of patients.


Diseases of The Esophagus | 2009

Inverse correlation between NKG2D expression on CD8+ T cells and the frequency of CD4+CD25+ regulatory T cells in patients with esophageal cancer.

Tomohiro Osaki; Hiroaki Saito; Youji Fukumoto; Yosinori Yamada; Kenji Fukuda; Shigeru Tatebe; Shunichi Tsujitani; Masahide Ikeguchi

Although malignant diseases are known to be associated with immune suppression, detailed mechanisms of this phenomenon are still unknown. NKG2D is an activating cell surface receptor expressed by natural killer (NK) cells and CD8+ T cells, and it has been reported that NKG2D engagement is extremely important for T cell activation. In the current study, NKG2D expression on CD8+ T cells and the frequency of CD4+ CD25+ regulatory T (Treg) cells were determined by multicolor flow cytometry to investigate one of the mechanisms responsible for immune evasion in esophageal cancer patients. NKG2D expression on CD8+ T lymphocytes in esophageal cancer patients was significantly lower than in those of normal controls. NKG2D expression in T3/T4 esophageal cancer was significantly lower than that in T1/T2 esophageal cancer. CD8+ T cells from patients with lymph node metastasis expressed significantly lower NKG2D than those without lymph node metastasis. Moreover, significantly lower NKG2D expression was observed in stage III/IV cancer in comparison with stage I/II. The frequency of CD4+CD25+ Treg cells in esophageal cancer patients was significantly higher than those in normal controls. NKG2D expression on CD8+ T cells was significantly inversely correlated with the frequency of CD4+CD25+ Treg cells in esophageal cancer patients. Our data indicates that decreased NKG2D expression on CD8+ T cells is correlated with disease severity. Decreased NKG2D expression and an increase in Treg cells may be one of the key mechanisms responsible for immune evasion in esophageal cancer.


Gastric Cancer | 2006

Detection of cancer cells and gene expression of cytokines in the peritoneal cavity in patients with gastric cancer

Youji Fukumoto; Masahide Ikeguchi; Sachiko Matsumoto; Masashi Inoue; Tomohiro Osaki; Kenji Fukuda; Hiroaki Saito; Shigeru Tatebe; Shunichi Tsujitani

BackgroundThe gene expression of the cytokines interleukin-2 (IL-2) and IL-10 in peritoneal washings was examined in relation to the presence of cancer cells in the peritoneal cavity in patients with gastric cancer.MethodsTotal RNA was extracted from 50-ml peritoneal wash samples from 124 patients (gastric cancer, n = 110; controls, n = 14). Carcinoembrionic antigen (CEA) messenger RNA (mRNA) was used to identify the number of cancer cells in peritoneal wash samples by a real-time reverse transcription-polymerase chain reaction (RT-PCR) method, which method was also used to assay the IL-2 and IL-10 gene expression levels.ResultsIn the 14 control samples, CEA mRNA was not detected, while CEA mRNA was detected in 2 of the 51 stage I gastric cancer patients. Thus, the specificity of this method for the detection of cancer cells in peritoneal wash samples was 97% (63/65). The CEA-based real-time RT-PCR method demonstrated greater prognostic impact than the traditional cytological method. IL-2 gene expression in peritoneal wash samples that were CEA mRNA-positive was suppressed compared with that in peritoneal wash samples that were CEA mRNA-negative, while IL-10 gene expression did not differ according to the CEA mRNA findings.ConclusionThe detection of small numbers of cancer cells in peritoneal wash samples from patients with advanced gastric cancer is a good marker for peritoneal metastatic recurrence. In the peritoneal cavity, cancer cells may escape from immune surveillance by controlling the expression of cytokines.


International Surgery | 2012

Prognosis of Patients With Gastric Cancer Who Underwent Proximal Gastrectomy

Masahide Ikeguchi; Abdul Kader; Seigo Takaya; Youji Fukumoto; Tomohiro Osaki; Hiroaki Saito; Shigeru Tatebe; Toshiro Wakatsuki


Journal of Gastrointestinal Cancer | 2013

Treatment of Patients with Stage IV Gastric Cancer

Masahide Ikeguchi; Abdul Kader; Seigo Takaya; Youji Fukumoto; Tomohiro Osaki; Hiroaki Saito; Shigeru Tatebe; Toshiro Wakatsuki


Yonago Acta Medica | 2015

Usefulness of Preoperative Assessment of Perigastric Vascular Anatomy by Dynamic Computed Tomography for Laparoscopic Gastrectomy.

Tomohiro Osaki; Hiroaki Saito; Yuki Murakami; Kozo Miyatani; Hirohiko Kuroda; Tomoyuki Matsunaga; Youji Fukumoto; Masahide Ikeguchi


Molecular and Clinical Oncology | 2013

Usefulness of palliative prognostic score in the treatment of patients with non-resectable gastric cancer

Masahide Ikeguchi; Abdul Kader; Miwa Yoshimoto; Seigo Takaya; Joji Watanabe; Youji Fukumoto; Tomohiro Osaki; Hiroaki Saito; Shigeru Tatebe; Toshiro Wakatsuki

Collaboration


Dive into the Youji Fukumoto's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge